Adelphi Nursing And Rehabilitation Center | |
1801 Metzerott Road, Adelphi, Maryland 20783 | |
(301) 434-0500 | |
Name | Adelphi Nursing And Rehabilitation Center |
---|---|
Location | 1801 Metzerott Road, Adelphi, Maryland |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 170 |
Occupancy Rate | 77.53% |
Medicare ID (CCN) | 215064 |
Legal Business Name | Adelphi Nursing And Rehabilitation Center Llc |
Ownership Type | For Profit - Limited Liability Company |
NPI Number | 1013963313 |
Organization Name | HEARTLAND OF ADELPHI MD LLC |
Doing Business As | MANORCARE HEALTH SERVICES - ADELPHI |
Address | 1801 Metzerott Rd, Adelphi, MD 20783 |
Phone Number | 301-434-0500 |
News Archive
Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months.
Natural Health Trends Corp., an international direct selling company, today announced that it has decided not to pursue a costly appeal of a delisting notice it received from The Nasdaq Stock Market on November 2, 2009. This decision was reached as part of the Company's overall strategy to improve cost-effectiveness and focus its resources on revenue-generation activities and support for member activities.
Scientists at the University of Massachusetts Medical School have performed the first CRISPR/Cas9 screen to discover human proteins that Zika virus needs for replication.
While researchers around the world race to develop an effective and safe COVID-19 vaccine, a team from the San Diego Supercomputer Center (SDSC) at UC San Diego contributed to a study led by Vanderbilt Vaccine Center of Vanderbilt University Medical Center (VUMC) on T cell receptors, which play a vital role in alerting the adaptive immune system to mount an attack on invading foreign pathogens including the Coronavirus SARS-CoV-2.
GlaxoSmithKline and Reliant Pharmaceuticals Inc. have announced that they had reached an agreement under which Reliant will be acquired by GSK for $1.65 billion (800 million pounds Sterling) in cash.
› Verified 3 days ago
NPI Number | 1659904738 |
Organization Name | ADELPHI NURSING AND REHABILITATION CENTER LLC |
Address | 1801 Metzerott Rd, Adelphi, MD 20783 |
Phone Number | 301-434-0500 |
News Archive
Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months.
Natural Health Trends Corp., an international direct selling company, today announced that it has decided not to pursue a costly appeal of a delisting notice it received from The Nasdaq Stock Market on November 2, 2009. This decision was reached as part of the Company's overall strategy to improve cost-effectiveness and focus its resources on revenue-generation activities and support for member activities.
Scientists at the University of Massachusetts Medical School have performed the first CRISPR/Cas9 screen to discover human proteins that Zika virus needs for replication.
While researchers around the world race to develop an effective and safe COVID-19 vaccine, a team from the San Diego Supercomputer Center (SDSC) at UC San Diego contributed to a study led by Vanderbilt Vaccine Center of Vanderbilt University Medical Center (VUMC) on T cell receptors, which play a vital role in alerting the adaptive immune system to mount an attack on invading foreign pathogens including the Coronavirus SARS-CoV-2.
GlaxoSmithKline and Reliant Pharmaceuticals Inc. have announced that they had reached an agreement under which Reliant will be acquired by GSK for $1.65 billion (800 million pounds Sterling) in cash.
› Verified 3 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months.
Natural Health Trends Corp., an international direct selling company, today announced that it has decided not to pursue a costly appeal of a delisting notice it received from The Nasdaq Stock Market on November 2, 2009. This decision was reached as part of the Company's overall strategy to improve cost-effectiveness and focus its resources on revenue-generation activities and support for member activities.
Scientists at the University of Massachusetts Medical School have performed the first CRISPR/Cas9 screen to discover human proteins that Zika virus needs for replication.
While researchers around the world race to develop an effective and safe COVID-19 vaccine, a team from the San Diego Supercomputer Center (SDSC) at UC San Diego contributed to a study led by Vanderbilt Vaccine Center of Vanderbilt University Medical Center (VUMC) on T cell receptors, which play a vital role in alerting the adaptive immune system to mount an attack on invading foreign pathogens including the Coronavirus SARS-CoV-2.
GlaxoSmithKline and Reliant Pharmaceuticals Inc. have announced that they had reached an agreement under which Reliant will be acquired by GSK for $1.65 billion (800 million pounds Sterling) in cash.
› Verified 3 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 6 |
Total Amount of Fines in Dollars | $16250 |
Number of Payment Denials | 0 |
Total Number of Penalties | 6 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 27.58 | 14.46 |
Percentage of long-stay residents who lose too much weight | 11.71 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 57.14 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.26 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 2.34 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0.81 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 1.47 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 82.56 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 15.59 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 86.4 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 2.49 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 36.57 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 6.06 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 14.88 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 88.48 | 95.98 |
Percentage of short-stay residents who made improvements in function | 66.31 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 96.89 | 82.93 |
News Archive
Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months.
Natural Health Trends Corp., an international direct selling company, today announced that it has decided not to pursue a costly appeal of a delisting notice it received from The Nasdaq Stock Market on November 2, 2009. This decision was reached as part of the Company's overall strategy to improve cost-effectiveness and focus its resources on revenue-generation activities and support for member activities.
Scientists at the University of Massachusetts Medical School have performed the first CRISPR/Cas9 screen to discover human proteins that Zika virus needs for replication.
While researchers around the world race to develop an effective and safe COVID-19 vaccine, a team from the San Diego Supercomputer Center (SDSC) at UC San Diego contributed to a study led by Vanderbilt Vaccine Center of Vanderbilt University Medical Center (VUMC) on T cell receptors, which play a vital role in alerting the adaptive immune system to mount an attack on invading foreign pathogens including the Coronavirus SARS-CoV-2.
GlaxoSmithKline and Reliant Pharmaceuticals Inc. have announced that they had reached an agreement under which Reliant will be acquired by GSK for $1.65 billion (800 million pounds Sterling) in cash.
› Verified 3 days ago
Adelphi Nursing And Rehabilitation Center Location: 1801 Metzerott Road, Adelphi, Maryland 20783 Phone: (301) 434-0500 | |
Hillhaven Nursing And Rehabilitation Center Location: 3210 Powder Mill Road, Adelphi, Maryland 20783 Phone: (301) 937-3939 |